|
Irinotecan in Treating Patients with Refractory Solid Tumors and Liver Dysfunction Clinical Trials Info presented on Clinical Trials Search is not intended to be a substitute for certified medical advice, visits or professional assistance using a real physician. We are not physicians. Always consult your dr. about Irinotecan in Treating Patients with Refractory Solid Tumors and Liver Dysfunction conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Irinotecan in Treating Patients with Refractory Solid Tumors and Liver Dysfunction Clinical research trials and Irinotecan in Treating Patients with Refractory Solid Tumors and Liver Dysfunction health trials happen in many of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new drugs. The function of the studies / projects is to resolve particular human medical questions. Clinical trials are a popular manner for mDs, government agencies, and private sector corporations to discover remedies for all varieties of circumstances, like Irinotecan in Treating Patients with Refractory Solid Tumors and Liver Dysfunction. Irinotecan in Treating Patients with Refractory Solid Tumors and Liver Dysfunction Clinical Trials and other clinical trials allow volunteers to obtain healthcare treatment options before they are available to the masses. Some times the participants undergo professional assistance for free of charge, and occasionally they are paid for their time. Sometimes there is a cost for a Irinotecan in Treating Patients with Refractory Solid Tumors and Liver Dysfunction clinical trial. Human subjects often get the best healthcare available for their Irinotecan in Treating Patients with Refractory Solid Tumors and Liver Dysfunction condition. Dangers are a reality, however, and may include additional or frequent mD visits, healthcare dangers (potentially life-jeopardising), and/or the treatment being ineffectual. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Irinotecan in Treating Patients with Refractory Solid Tumors and Liver Dysfunction  Irinotecan in Treating Patients with Refractory Solid Tumors and Liver Dysfunction
Irinotecan in Treating Patients with Refractory Solid Tumors and Liver Dysfunction
For Condition: Chemotherapy,Unspecified adult solid tumor,Neoplasms, solid tumor,Liver Dysfunction
Status: Completed
Sponsor(s): Pfizer ,
Synopsis: Drugs used in chemotherapy us different ways to stop tumor cells from dividing so they stop growing or die. Irinotecan may be effective in treating patients with refractory solid tumors and liver dysfunction.
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary. Inclusion Criteria: Histological proof of malignant solid tumor that is refractory to standard forms of therapy or for which no known curative therapy exists; Measurable or evaluable disease; At least 6 weeks since prior chemotherapy with nitrosoureas; At least 28 days since prior anticancer therapy and recovered; At least 4 weeks since prior radiation therapy and recovered; Age 18 years or older; SWOG 0-2; Life expectancy of at least 12 weeks; Segmented neutrophils with bands at least 1,500/mm3; Hemoglobin at least 9.0 g/dL and platelet count at least 100,000/mm3; Prothrombin time and partial thromboplastin time no greater than 2.0 times control; INR no greater than 3.0 times control; Concurrent use of coumadin allowed only if dose is stable and prothrombin time and INR is stable; Total serum bilirubin at least 1.5 but no greater than 5.0 times upper limit of normal; SGOT/SGPT no greater than 5 times upper limit of normal; SGOT/SGPT at least 1.5 but no greater than 20.0 times upper limit of normal; Creatinine no greater than 2 Exclusion Criteria: Patients expressing tumor markers as their only evidence of disease or who have previously irradiated areas that have not increased in size; Prior chemotherapy treatment with irinotecan and mitomycin; Prior abdominal and/or pelvic radiation therapy; Current history of hepatitis B infection or positive test for hepatitis B surface antigen; Hepatic encephalopathy including somnolence, confusion, or asterixis; History of myocardial infarction within 6 months or history of congestive heart failure (CHF); clinical evidence of CHF; Evidence of arrhythmia in patients with history of cardiac arrhythmia; Uncontrolled hypertension, unstable angina, active CHF, or serious uncontrolled cardiac arrhythmia; Interstitial pneumonia or fibroid lung (patients must have large pleural effusions drained and sclerosed or controlled prior to study; patients must have clinically apparent ascites drained prior to irinotecan treatment); CNS metastases or carcinomatous meningitis; Concurrent use of anticonvulsants; Active or uncontroll
Total Enrollment:
Location and Contact Information:
Research Center
Detroit, Michigan, 48201
United States
Research Center
Marshfield, Wisconsin, 54449
United States
Research Center
Nashville, Tennessee, 37232
United States
Research Center
New Brunswick, New Jersey, 08901
United States
Additional Information:
Study ID Numbers: M/6475/0017;
Study Start Date:
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00037804
Other Liver Dysfunction Studies:
1. Irinotecan in Treating Patients with Refractory Solid Tumors and Liver Dysfunction
Related Studies:
Other Liver Dysfunction Clinical Trials
Other New Jersey Clinical Trials
Other New Brunswick Clinical Trials
Irinotecan in Treating Patients with Refractory Solid Tumors and Liver Dysfunction
|
|
|
|
|
|
|
|
